## SECURITIES AND EXCHANGE COMMISSION

# FORM 4

Statement of changes in beneficial ownership of securities

Filing Date: **2025-03-11** | Period of Report: **2025-03-08** SEC Accession No. 0001093557-25-000062

(HTML Version on secdatabase.com)

## **REPORTING OWNER**

## Sylvain Jereme M

CIK:1681267

Type: 4 | Act: 34 | File No.: 000-51222 | Film No.: 25729493

Mailing Address 6340 SEQUENCE DRIVE SAN DIEGO X1 92121

## **ISSUER**

### **DEXCOM INC**

CIK:1093557| IRS No.: 330857544 | State of Incorp.:DE | Fiscal Year End: 1231 SIC: 3841 Surgical & medical instruments & apparatus

Mailing Address 6340 SEQUENCE DRIVE SAN DIEGO CA 92121 Business Address 6340 SEQUENCE DRIVE SAN DIEGO CA 92121 8582000200

# FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

UMB APPR	OVAL
OMB Number:	3235-0287
Expires:	02/28/2011
Estimated average b	urden
hours per response	0.5

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address Sylvain Jereme		son *	2. Issuer Name <b>and</b> Ticker or Trading Symbol  DEXCOM INC [DXCM]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner				
()			3. Date of Earliest Transaction (Month/Day/Year) 03/08/2025	LVP, Chief Financal Officer				
6340 SEQUENC	E DRIVE							
SAN DIEGO, CA	(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing (Check applicable line) X Form Filed by One Reporting Person Form Filed by More than One Reporting Person				
(City)	(State)	(Zip)						

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/ Day/Year)	2A. Deemed Execution Date, if	3. Transaction Code (Instr. 8)					Securities Beneficially Owned	6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
		any (Month/ Day/Year)	Code	<b>V</b>	Amount	(A) or (D)	Price	Following Reported Transaction(s) (Instr. 3 and 4)	or Indirect (I) (Instr. 4)	
Common Stock	03/08/2025		<u>A</u>		35,906 <sup>(1)</sup>	A	\$ 0	119,684	D	
Common Stock	03/08/2025		<u>A</u>		22,798 <sup>(2)</sup>	A	\$ 0	142,482	D	
Common Stock	03/10/2025		<u>s</u>		2,670	D	\$73.217 <sup>(<u>3</u>)</sup>	139,812	D	
Common Stock	03/10/2025		<u>s</u>		3,203	D	\$74.0404 <sup>(<u>4</u>)</sup>	136,609	D	
Common Stock	03/10/2025		<u>S</u>		1,127	D	\$74.7023 <sup>(5)</sup>	135,482 <sup>(<u>6</u>)</sup>	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Security (Instr. 3)	or Exercise Price of	3. Transaction Date (Month/ Day/Year)	3A. Deemed Execution Date, if any (Month/ Day/ Year)	4. Transa Code (Instr. 8		5. Numb of Deriv Secu Acqu (A) or Dispo of (D) (Instr. 4, and	ative rities ired rosed )	6. Date Exer and Expiratio (Month/Day/	n Date	7. Title a Amount of Securitie Underlyin Derivativ Security and 4)	of s ng re	of	Beneficially Owned Following Reported Transaction(s)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number					

1 1				l				l	
1 1				l		lof			l
1 1				l		١٠.		l	
1 1				l		Shares			l
1 1				l		Silales			l
				l	I .			1	

#### **Explanation of Responses:**

- 1. Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock.
- 2. Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting from the date of grant as follows: 1/2 shall vest on March 8, 2026, 1/8 shall vest on May 22, 2026, 1/8 shall vest on August 22, 2026, 1/8 shall vest on November 8, 2026, and the remaining balance shall vest on March 8, 2027. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock.
- 3. This transaction was executed in multiple trades at prices ranging from \$72.56 to \$73.51. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
- **4.** This transaction was executed in multiple trades at prices ranging from \$73.56 to \$74.52. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
- 5. This transaction was executed in multiple trades at prices ranging from \$74.61 to \$74.74. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
- **6.** Included in this number are 83,328 unvested restricted stock units, 35,906 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 17,368 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 7,256 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 252 shares acquired under the Issuer's 2015 Employee Stock Purchase Plan on February 28, 2025.

#### **Signatures**

/s/ Jereme M. Sylvain

03/11/2025

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\*\* Signature of Reporting Person

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.